Ubrelvy is a newer abortive medication for migraines which is classified as a CGRP-inhibitor. A CGRP-inhibitor is drug that blocks CGRP which causes pain cascade associated with migraine.
This is drug, also known as ubrogepant, is used as an acute treatment for migraine. Some studies have shown
The clinical trials for Ubrelvy showed that the side effects included nausea and fatigue and were the same as placebo.
One study showed that a significant percentage of study participants were pain-free within 2 hours of taking Ubrelvy and that many had complete relief of symptoms of nausea and sensitivity to light and sound.
Additionally, this medication is safe for patients who cannot use triptans such as those with cardiovascular disease including as high blood pressure, high cholesterol, and stroke.
For more information about trying Ubrelvy, CALL THE MANHATTAN CENTER FOR HEADACHE & NEUROLOGY. We look forward to seeing you!
By: Brooke Steiger NP